Skip to content
10-Q

Quarterly Report

ACCENDRA HEALTH INC/VA/ ACH

0001104659-26-058465

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 76.43M sh
Shares Diluted Q1 2026 · Mar 31, 2025 77.27M sh
Shares Outstanding Q1 2026 · Mar 31, 2026 76.58M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $0
Stock Repurchased Q1 2026 · Mar 31, 2025 $1.5M
Capex Q1 2026 · Mar 31, 2026 $41.65M
Capex Q1 2026 · Mar 31, 2025 $45.79M
Short Term Debt Q1 2026 · Mar 31, 2026 $581.25M
Short Term Debt Q1 2026 · Dec 31, 2025 $250M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $336.88M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $281.99M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$464.77M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$460.98M
Stockholders Equity Q1 2026 · Mar 31, 2025 $570.98M
Stockholders Equity Q1 2026 · Dec 31, 2024 $586.36M
Current Liabilities Q1 2026 · Mar 31, 2026 $1.2B
Current Liabilities Q1 2026 · Dec 31, 2025 $947.08M
Total Liabilities Q1 2026 · Mar 31, 2026 $2.88B
Total Liabilities Q1 2026 · Dec 31, 2025 $2.91B
Current Assets Q1 2026 · Mar 31, 2026 $588.5M
Current Assets Q1 2026 · Dec 31, 2025 $547.87M
Total Assets Q1 2026 · Mar 31, 2026 $2.42B
Total Assets Q1 2026 · Dec 31, 2025 $2.45B
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.08
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.32
Eps Basic Q1 2026 · Mar 31, 2026 −$0.08
Eps Basic Q1 2026 · Mar 31, 2025 −$0.32
Sga Expense Q1 2026 · Mar 31, 2026 $255.23M
Sga Expense restated Q1 2026 · Mar 31, 2025 $262.37M
Net Income Q1 2026 · Mar 31, 2026 −$6.47M
Net Income Q1 2026 · Mar 31, 2025 −$24.98M
Operating Income Q1 2026 · Mar 31, 2026 $17.13M
Operating Income restated Q1 2026 · Mar 31, 2025 $19.79M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $349.75M
Cost Of Revenue restated Q1 2026 · Mar 31, 2025 $354.64M
Revenue Q1 2026 · Mar 31, 2026 $627.78M
Revenue restated Q1 2026 · Mar 31, 2025 $673.88M